Traws Pharma, Inc. (TRAW) Stock Forecast
TRAW analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 2 analysts
- Price target
- $1.00 average of analyst targets
- Upside to target
- +170.8% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.21
- 52-week range
- $0.37 – $3.07
TRAW analyst ratings
2 analystsNumber of analysts at each rating.
TRAW price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TRAW earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.20 | −$0.20 | — | — | 1 |
| Current fiscal year (2026) | −$1.33 | −$1.33 | −$1.33 | −$2.35 | +43.5% | 1 |
| Next fiscal year (2027) | −$1.88 | −$1.88 | −$1.88 | −$1.33 | −41.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TRAW revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
TRAW EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TRAW EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.63 | −$0.36 | −$0.36 | −$0.36 | −$0.20 | −68.3% | 1 up · 0 down |
| Current fiscal year (2026) | −$3.13 | −$1.82 | −$1.82 | −$1.82 | −$1.33 | −57.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$4.03 | −$1.98 | −$1.98 | −$1.98 | −$1.88 | −53.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TRAW earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TRAW beat in 9 of 12.
What analysts expect from TRAW
2 analysts cover Traws Pharma; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.00, 170.8% above the latest close of $0.37. Analysts expect earnings of −$1.33 per share for 2026, +43.5% from a year earlier. For 2027 the average estimate is −$1.88 per share. Traws Pharma beat the EPS estimate in 9 of the last 12 quarters.
Related: TRAW income statement, TRAW key metrics, TRAW chart. See the TRAW stock overview for the latest quote and news.
TRAW forecast FAQ
What is Traws Pharma's price target?
The average analyst price target for Traws Pharma is $1.00, 170.8% above the latest close of $0.37.
Is Traws Pharma a buy, hold or sell?
Of 2 analysts covering Traws Pharma, 0 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Traws Pharma's EPS forecast?
Analysts forecast −$1.33 per share for 2026 (range −$1.33 to −$1.33); for 2027 the estimate is −$1.88.
When does Traws Pharma report earnings?
Traws Pharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.21.
Does Traws Pharma usually beat earnings estimates?
Traws Pharma reported EPS at or above the analyst estimate in 9 of the last 12 quarters.